3Massimiliano Fabbiani, Laura Bracciale, Maria Doino, et al. Tenofovir discontinuation could predispose to urolithiasis in atazanavir-treated patients [J]. Journal of Infection, 2011, 62 (4): 319-322.
5Ly T, Ruiz M. Prolonged QT interval and torsades de pointes associated with atazanavir therapy [J]. Clin Infect Dis, 2007, 44 (6): 67-68.
6Pyrko P, Kardosh A, Wang W, et al. HIV-1 protease in hibitors nelfinavir and atazanavir induce malignant glioma death by triggering endoplasmie retieulum stress [J]. Cancer Research, 2006, 67 (22): 92-97.
7G Bold, A Fassler, H G Capraro, et al. New aza-dipeptide analogues as potent and orally absorbed HIV 1 protease inhibitors: candidates for clinical development [J]. Researchgate, 1998, 41 (18): 387-401.
8K SRINIVASU. A Validated RP-HPLC Method for the Determination of Atazanavir in Pharmaceutical Dosage Form [J]. E-Journal of Chemistry, 2011, 8 (1): 453-456.
9Suddhasattya Dey. Method Development and Validation for the Estimation of Atazanavir in Bulk and Pharmaceutical Dosage Forms and Its Stress Degradation Studies Using UV Vis Spectrophotometric Method [J]. International Journal of Pharma and Bio Sciences, 2010, 1 (3) :403-414.
10Sreenivasa Rao Chitturi. Gradient RP-HPLC method for the determination of potential impurities in atazanavir sulfate [J]. Journal of Pharmaceutical and Biomedical Analysis, 2011, 1 (2): 31-47.
